Support By : Li-lab
PATHWAY_NAME | REACTOME_ID | KEGG_ID | DRUG_NAME | PUBCHEM_CID | Datasource |
---|---|---|---|---|---|
Type I diabetes mellitus | R-HSA-5683209 | map04940 | helveticoside | 441860 | drug-path |
B cell receptor signaling pathway | R-HSA-983705 | map04662 | lanatoside C | 656630 | drug-path |
Alzheimer's disease | R-HSA-1643685 | 0 | lanatoside C | 656630 | drug-path |
Huntington's disease | R-HSA-1643685 | 0 | lanatoside C | 656630 | drug-path |
Olfactory transduction | R-HSA-9751605 | map04740 | lanatoside C | 656630 | drug-path |
Systemic lupus erythematosus | R-HSA-977105 | map05322 | lanatoside C | 656630 | drug-path |
Bladder cancer | R-HSA-9700206 | map05219 | lanatoside C | 656630 | drug-path |
MAPK signaling pathway | R-HSA-9652817 | map04010 | lanatoside C | 656630 | drug-path |
Parkinson's disease | R-HSA-1643685 | 0 | lanatoside C | 656630 | drug-path |
Ribosome | R-HSA-5368277 | map03010 | lanatoside C | 656630 | drug-path |
Chronic myeloid leukemia | R-HSA-9680350 | map05220 | lanatoside C | 656630 | drug-path |
Graft-versus-host disease | R-HSA-1643685 | map05332 | lanatoside C | 656630 | drug-path |
Natural killer cell mediated cytotoxicity | R-HSA-5218921 | map04650 | lanatoside C | 656630 | drug-path |
Hematopoietic cell lineage | R-HSA-173752 | map04640 | lanatoside C | 656630 | drug-path |
Neuroactive ligand-receptor interaction | R-HSA-5632681 | map04080 | lanatoside C | 656630 | drug-path |
Taste transduction | R-HSA-162582 | map04742 | lanatoside C | 656630 | drug-path |
Autoimmune thyroid disease | R-HSA-1643685 | map05320 | lanatoside C | 656630 | drug-path |
Antigen processing and presentation | R-HSA-1236975 | map04612 | lanatoside C | 656630 | drug-path |
Leukocyte transendothelial migration | R-HSA-8950732 | map04670 | lanatoside C | 656630 | drug-path |
Cell adhesion molecules (CAMs) | R-HSA-1031690 | 0 | lanatoside C | 656630 | drug-path |